▁the ▁treatment ▁of ▁non - small ▁cell ▁lung ▁cancer ▁( NS CLC ), ▁C ushing ' s ▁disease , ▁le uk emia , ▁H IV ▁in fection , ▁Park inson ’ s ▁disease , ▁her pes ▁simple x ▁in fection , ▁c yst ic ▁fib ros is ▁and ▁the ▁mechan isms ▁of ▁chron ic ▁infl amm ation ▁dis orders . ▁ ▁Sel ic ic lib ▁is ▁a ▁ 2 , 6 , 9 - subst it uted ▁pur ine ▁analog . ▁Its ▁structure ▁in ▁complex ▁with ▁CD K 2 ▁was ▁determined ▁in ▁ 1 9 9 6 . ▁ ▁Sel ic ic lib ▁in hib its ▁CD K 2 / E , ▁CD K 2 / A , ▁CD K 7 ▁and ▁CD K 9 . ▁ ▁Us es ▁ ▁Sel ic ic lib ▁has ▁been ▁found ▁to ▁produce ▁apo pt osis ▁in ▁treated ▁cancer ous ▁cells ▁of ▁non - small ▁cell ▁lung ▁cancer ▁( NS CLC ) ▁and ▁other ▁can cers . ▁ ▁Sel ic ic lib ▁has ▁previously ▁under g one ▁Ph ase ▁II a ▁clin ical ▁tri als , ▁in ▁ 2 4 0 ▁NS CLC ▁patients ▁as ▁a ▁combined ▁do se ▁with ▁existing ▁first - ▁and ▁second - line ▁treat ments . ▁ ▁In ▁the ▁current ▁AP P RA I SE ▁trial , ▁the ▁research ▁drug ▁is ▁under going ▁Ph ase ▁II b ▁clin ical ▁trial ▁as ▁a ▁mon other apy ▁for ▁NS CLC ▁in ▁third - line ▁patients . ▁The ▁side - effect s ▁reported ▁in ▁Ph ase